Nanoco Group PLC

Appointment of Interim CFO

Published on 3/10/2014

Nanoco Group plc (AIM: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, announces the appointment of Mark Sullivan as the Company’s Interim CFO. Mark has provided accountancy services to Nanoco for the past nine years through his advisory company Assist LLP. His appointment as Interim CFO will enable Colin White, Nanoco’s CFO, to take leave of absence from the Company for personal reasons. Mark is not being appointed to the Board but will report directly to the Board during this interim period.

Mark began working with Nanoco in 2005 and has been closely involved in producing Nanoco’s accounts since that time. He also played an important advisory role in Nanoco’s flotation on AIM in 2009.

For further information, please contact:

Tel: +44 (0) 161 603 7900
Michael Edelman, Chief Executive Officer

Mark Sullivan, Interim Chief Financial Officer

Canaccord Genuity – Nomad and Joint Broker
Tel: +44 (0) 20 7523 8000
Simon Bridges
Cameron Duncan

Liberum – Joint Broker
Tel: +44 (0) 20 3100 2000
Simon Atkinson
Richard Bootle

Tel: +44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie Cowles

Notes for editors:

About Nanoco Group plc
Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nano-materials for use in multiple applications including LCD displays, lighting, solar cells and bio-imaging. In the display market, it has an exclusive manufacturing and marketing licensing agreement with The Dow Chemical Company.

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based in Concord, MA. Nanoco also has business development offices in Japan, Korea and Taiwan. Its technology is protected worldwide by a large and growing patent estate.

Nanoco began trading on the AIM market of the London Stock Exchange in May 2009 under the ticker symbol NANO. For further information please visit: